Methods: One-hundred and twenty patients with normal ventricle function and no history of diabetes mellitus (DM) were randomly divided into three groups. During the operation, 10 IU/L of crystalized insulin-added blood cardioplegia was administered to the patients in group 1 (n=40) and group 2 (n=40), and standard blood cardioplegia was used in group-3 (n=40). In addition, GIK solution was started before the removal of cross-clamp (CC) period in group 2. The blood samples from arterial and coronary sinus were collected before CC application (T0), before CC removal (T1) and 0, 5th, 10th, and 15th minutes (T2-T3-T4-T5) after CC removal. Hemodynamic parameters were measured at the 30th minute after anesthesia induction and 1st and 24th hours following surgery. During the peri- and postoperative course, the need for defibrillation, inotropic and intraaortic balloon pump support, the incidence of postoperative arrythmias, duration of intubation, intensive care unit stay and hospitalization were recorded.
Results: The levels of arterial and coronary sinus lactate were significantly lower in group 2 compared to group 3 in the 5th, 10th, and 15th minutes. The blood glucose levels of arterial and coronary sinus were significantly higher in group 3. In group 2, the incidence of postoperative arrythmias and requirement for inotropic support was less than that of group 1 and group 3 (p<0.05).
Conclusion: After CABG, in the reperfusion period, persistant release of lactate or higher lactate levels demonstarate that myocardial protection was unsatisfactory and the recovery of aerobic metabolism was diminished perioperatively. Glucose-insulinpotassium solution combined with insulin cardioplegia decreases the myocardial lactate level, incidence of arrythmias, and requirement for inotropic support and leads to better myocardial protection.
During the aortic cross-clamp (CC) period, hypothermia and cardioplegia are the most widely accepted methods for myocardial protection. However, myocardial ischemia and postischemic reperfusion injury has still been observed. The most sensitive parameter that demonstrates myocardial preservation are coronary sinus blood lactate levels.
In the period of reperfusion, glucose-insulin-potassium (GIK) solution has been tried for the prevention of myocyte injury, reflected by contractile dysfunction and/or intractable malign arrhythmias.[3] High dose insulin administration shifts the myocardial metabolism towards glycogenesis and glycolysis. By favoring the use of glucose from the glycogen stores, this shift diminishes the rise of coronary sinus lactate levels during the ischemic period. In addition, GIK solution has been shown to decrease the incidence of malignant arrhythmias.[4]
In this study, we aimed to investigate the hemodynamic and metabolic effects of insulin cardioplegia, GIK solution combined with insulin cardioplegia and only blood cardioplegia on peri- and postoperative recovery periods of patients who underwent elective coronary artery bypass grafting (CABG).
In group 1 (n=40); cardiac arrest was induced with antegrade and retrograde cold intermittent blood cardioplegia with insulin concentration of 10 IU/L.
In group 2 (n=40); cardiac arrest was achieved by antegrade and retrograde cold intermittent blood cardioplegia with insulin at the concentration of 10 IU/L. In this group, GIK solution consisting of 10% 500 ml dextrose, 20 IU crystalized insulin, 60 mmol 22.5% potassium chloride (KCL) was started before the removal of CC and infused at the rate of 0.75 ml/kg/hour for 24 hours following surgery.
In group 3 (n=40); cold intermittent blood cardioplegia was used. According to a sliding scale, insulin was given to maintain blood glucose levels between 150-200 mg peroperatively.
Anesthetic and surgical technique
Patients were premedicated with oral diazepam
(0.15 mg/kg), intramuscular morphine sulfate (0.15
mg/kg) and scopolamine (0.01 mg/kg) 45 minutes
prior to surgery. Routine electrocardiography (ECG)
monitoring with two derivations including DII and
V5 was performed. Left radial arterial catheter and
Swan-Ganz catheter (Biosensors International 7 F TD
1703 HX, Philadelphia, Penn, USA) were placed under
local anesthesia. After induction of anesthesia using
15 mcg/kg fentanyl, 2 mg/kg propofol, 0.1 mg/kg pancuronium,
the patients were mechanically ventilated
with the settings of: FiO2=1.0, tidal volume (TV)=8-10
ml/kg, respiratory rate 12/minute, inspiration/expiration=
1/2. For maintenance, propofol (2 mg/kg/h) and
fentanyl (4 mcg/kg/h) infusions were used. In order to
keep hemodynamics in normal range, 1 MAC (minimum
alveolar concentration) of sevoflurane was added
on requirement. Hemodynamic parameters measured
at 30 minutes after induction (T0), 30 minutes after
bypass period (T1), postoperative first hour (T2), and
24 hours after surgery (T3) were mean arterial pressure
(MAP), central venous pressure (CVP), heart rate
(HR), mean pulmonary arterial pressure (MPAP) and
pulmonary capillary wedge pressure (PCWP). In each
group, arterial and coronary sinus blood samples were
obtained at the following time settings; before crossclamp
application (T2), just before cross-clamp removal
(T1), immediately after cross-clamp removal (T2)
and at following 5th (T3), 10th (T4), 15th (T5) minutes.
The collected blood samples were processed in the Stat
profile 5 (Nova Biomedical, seri no: MA 02454-9141
Waltham, USA) instrument for measurement of lactate
and glucose levels.
All patients were operated by the same surgeon. Cardiopulmonary bypass (CPB) was achieved using a roller pump and membrane oxygenator on mild hypothermia at 32 °C. Cardiac arrest was maintained by insulin-added blood cardioplegia in group 1 and 2, and only cold blood cardioplegia in group 3. After the each anastomosis was completed, 150-200 ml cold blood cardioplegia was additionally given through the saphenous vein grafts. 200 ml cold blood cardioplegia was given retrogradely with coronary sinus route in every 20 minutes periods. Terminal blood cardioplegia, hot shot, was given antegradely while LAD-LIMA anastomosis was performed. Blood cardioplegia contains blood in 1/3 concentration.
Inotropic agents were administered if the patients’ systolic blood pressure was below 80 mmHg and PCWP was above 18 mmHg.
Besides demographics, the data collected and analyzed included; duration of cross-clamp and CPB, defibrillation, requirement of inotropic support, intraaortic baloon pump placement, the incidence of atrial fibrillation, duration of intubation, ICU and hospital stay.
Statistical analysis
The parameters in this study were analyzed statistically
using the SPSS (Statistical Package for Social
Sciences, SPSS, Inc., Chicago, IL, USA) for Windows
13.0 version. The data was presented as mean ± standard
deviation (SD). For the assessment of data, qualitative
statistical tests as well as quantitative Kruskal Wallis
and Mann-Whithney U-tests were used. The differences
between repetitive measures at different time settings
were compared by Student t-test and Wilcoxon correlated
two sample test.
Qualitative data were compared using Chi-square and Fisher’s exact Chi-square tests. The relations between parameters were evaluated by the Spearman’s correlation coefficient. The significance was reported at the level of p<0.05.
Table 1: The distribution of the demographic data of groups
Table 2: The comparison of hemodynamic parameters between groups at different time settings
Fig 1: Arterial glucose levels.
Fig 2: Coronary sinus glucose levels.
Arterial and coronary sinus lactate levels were significantly lower in group 2 compared to group 3 at T3, T4, T5 periods (p<0.05; Fig. 3, 4).
Fig 3: The comparison of arterial lactate levels between groups at different time settings.
Fig 4: The comparison of coronary sinus lactate levels at different time settings.
The duration of aortic cross-clamp, CPB, ICU and hospital stay were similar (p>0.05). Although statistically not significant patients in group 2 were extubated earlier than in other groups. The requirement for inotropic support was significantly higher in group 3 compared to group 2 (p<0.05). The incidence of postoperative arrythmias were found to be statistically higher in group 3 than in group 2 (p<0.05; Table 3).
Table 3: The comparison of other variables during and after surgery
Under normal circumstances, lactate utilization by myocardial tissue is high and lactate is an acceptable substrate in the heart. The rate of its entry into the myocyte depends on the concentration gradient between blood and cytosol. Intracellular lactate concentration is related to the rate of pyruvate production and the reduction of pyruvate to lactate or its utilization via the Krebs cycle. At the beginning of reperfusion, myocardial lactate release is caused by increased glycogenolysis and anaerobic glucose oxidation.[10]
The positive contribution of insulin to the postischemic myocardium results from activation of PDH activity which triggers aerobic metabolism. Insulin neutralizes “insulin resistance ”caused by the increased concentration of free fatty acids and reduced myocardial glucose uptake. The increased concentration of free fatty acids and reduced myocardial glucose uptake leads to impairment of insulin neutralization or insulin resistance.[9] It was reported that IV (intravenous) infusion of insulin following CABG operations and/ or addition of insulin to blood cardioplegia stimulated the aerobic metabolism during reperfusion, prevented the plasma lactate release and improved left ventricular output work index.[11]
The main reason to the use of GIK solution in myocardial revascularization is that exogenous glucose increases ATP production via glycolytic pathway, decreases free fatty acid concentration in circulation and protects cellular viability. During reperfusion, both insulin and glucose renovates the substrates of the citric acid cycle thus supports the production of high energy phosphates. The resultant effect is protection of myocardial contractile function. The experimental and clinical studies showed that during ischemia and reperfusion periods the use of GIK has been effective in the production of substrates.[3,12,13]
In experimental studies it was shown that GIK infusion decreases tissue acidosis, the incidence of arrhythmias, protects contractile function and limits the necrotic areas. Glucose-insulin-potassium solution given during ischemia and reperfusion caused a significantly better positive response than the one given only during reperfusion. The other group of reperfusion only.[14] In a study on patients undergoing CABG due to unstable angina pectoris, GIK infusion resulted in higher cardiac index, less weight gain, shorter duration of intubation, ICU and hospital stay compared to the others.[15]
Rao et al.[16] compared the data from four groups of patients receiving either one of the four different solutions including; high or low dose glucose-added cardioplegic solutions with or without 10 IU/L of insulin. Patients receiving insulin cardioplegia with low dose glucose showed a better hemodynamic response than others. In another study, Rao et al.,[17] compared patients who developed low cardiac output syndrome following isolated CABG and those who did not. They reported that myocardial lactate release was higher in patients with low cardiac output syndrome. During the reperfusion period, persistant lactate release caused late recovery of aerobic myocardial metabolism.[17]
In a previous study performed in our clinic, we demonstrated that the administration of a single dose of insulin before cross-clamp removal caused a reduction in arterial and coronary sinus lactate levels and decreased the incidence of postoperative arrythmias.[18]
Rao et al.[19] reported no differences in the frequency of low cardiac output and peroperative myocardial infarction in high risk patients whether or not they received insulin cardioplegia. However, Lazar[20] criticised this paper due to the fact that the control group also received a similar amount of insulin because of high blood glucose levels. They argued that this might have affected the results and recommended substrate support continuously from the beginning of anesthesia to the reperfusion period. In our study, parallel to the Lazar’s results, the requirement for inotropic support was found to be significantly lower in patients receiving both insulin cardioplegia and GIK solution.
Lazar et al.[21] demonstrated in patients undergoing CABG for unstable angina that GIK solution decreased the incidence of atrial fibrillation and requirement for inotropic support.
Hynninen et al.[22] investigated the effects of insulin cardioplegia on postoperative atrial fibrillation incidence in high risk patients and found no difference. They posited that the differences of atrial fibrillation incidence could be related to the style of insulin administration. In order to prevent atrial fibrillation, they suggested insulin be given with blood cardioplegia and continued during the postoperative period.
In our study, the requirement for inotropic support and postoperative arrhythmias were significantly less in group 2 (insulin cardioplegia and postoperative infusion group) than the other groups. These findings are correlated with that of Lazar’s. In group 1 (insulin only cardioplegia group) the results were similar to those of group 2 but did not achieve statistical significance. Therefore, we thought that results from group 1 also resemble those of Hynninen, and insulin cardioplegia should be followed by GIK infusion for the best results.
In conclusion, insulin cardioplegia followed by GIK solution improves metabolic parameters, accelerates postoperative recovery, decreases the requirement for defibrillation, inotropic agents and incidence of arrythmias. On the other hand, insulin cardioplegia alone does not achieve changes that are statistically significant in the same parameters, but still results in an overall clinical improvement. For this reason, we believe that in patients with low risk who are undergoing elective coronary artery surgery, insulin cardioplegia can be administered with GIK solution because of an improvement in metabolic parameters and postoperative intensive care recovery and stay. Hovewer, there is need for larger group studies to show the benefits of this regimen on high risk patients.
Declaration of conflicting interests
The authors declared no conflicts of interest with respect
to the authorship and/or publication of this article.
Funding
The authors received no financial support for the
research and/or authorship of this article.
1) Young LH, McNulty PH, Morgan C, Deckelbaum LI, Zaret
BL, Barrett EJ. Myocardial protein turnover in patients with
coronary artery disease. Effect of branched chain amino acid
infusion. J Clin Invest 1991;87:554-60.
2) Franke UF, Korsch S, Wittwer T, Albes JM, Wippermann
J, Kaluza M, et al. Intermittent antegrade warm myocardial
protection compared to intermittent cold blood cardioplegia
in elective coronary surgery-do we have to change? Eur J
Cardiothorac Surg 2003;23:341-6.
3) Girard C, Quentin P, Bouvier H, Blanc P, Bastien O, Lehot
JJ, et al. Glucose and insulin supply before cardiopulmonary
bypass in cardiac surgery: a double-blind study. Ann Thorac
Surg 1992;54:259-63.
4) Quinn DW, Pagano D, Bonser RS. Glucose and insulin
influences on heart and brain in cardiac surgery. Semin
Cardiothorac Vasc Anesth 2005;9:173-8.
5) Roe BB, Hutchinson JC, Fishman NH, Ullyot DJ, Smith
DL. Myocardial protection with cold, ischemic, potassiuminduced
cardioplegia. J Thorac Cardiovasc Surg 1977;
73:366-74.
6) Conti VR, Bertranou EG, Blackstone EH, Kirklin JW,
Digerness SB. Cold cardioplegia versus hypothermia for
myocardial protection. Randomized clinical study. J Thorac
Cardiovasc Surg 1978;76:577-89.
7) Opie LH, Bruyneel K, Owen P. Effects of glucose, insulin
and potassium infusion on tissue metabolic changes within
first hour of myocardial infarction in the baboon. Circulation
1975;52:49-57.
8) Barton RN. Neuroendocrine mobilization of body fuels after
injury. Br Med Bull 1985;41:218-25.
9) Svensson S, Svedjeholm R, Ekroth R, Milocco I, Nilsson F,
Sabel KG, et al. Trauma metabolism and the heart. Uptake
of substrates and effects of insulin early after cardiac operations.
J Thorac Cardiovasc Surg 1990;99:1063-73.
10) Reves JG, Buttner E, Karp RB, Oparil S, McDaniel HG,
Smith LR. Elevated catecholamines during cardiac surgery:
consequences of reperfusion of the postarrested heart. Am J
Cardiol 1984;53:722-8.
11) Rao V, Mississauga CN, Merrante F. Insulin cardioplegia for
coronary bypass surgery. Circulation 1998;98(Suppl):I-612.
[Abstract]
12) Hearse DJ, Stewart DA, Braimbridge MV. Myocardial protection
during ischemic cardiac arrest. Possible deleterious
effects of glucose and mannitol in coronary infusates. J
Thorac Cardiovasc Surg 1978;76:16-23.
13) Díaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG,
Corvalán R, et al. Metabolic modulation of acute myocardial
infarction. The ECLA (Estudios Cardiológicos Latinoamérica)
Collaborative Group. Circulation 1998;98:2227-34.
14) Lazar HL, Zhang X, Rivers S, Bernard S, Shemin RJ.
Limiting ischemic myocardial damage using glucose-insulin-
potassium solutions. Ann Thorac Surg 1995;60:411-6.
15) Lazar HL. Enhanced preservation of acutely ischemic myocardium
and improved clinical outcomes using glucose-insulin-
potassium (GIK) solutions. Am J Cardiol 1997;80:90A-
93A.
16) Rao V, Borger MA, Weisel RD, Ivanov J, Christakis GT,
Cohen G, et al. Insulin cardioplegia for elective coronary
bypass surgery. J Thorac Cardiovasc Surg 2000;119:1176-84.
17) Rao V, Ivanov J, Weisel RD, Cohen G, Borger MA, Mickle
DA. Lactate release during reperfusion predicts low cardiac
output syndrome after coronary bypass surgery. Ann Thorac
Surg 2001;71:1925-30.
18) Savaşkan D, Yurtseven N, Tuygun AK, Aksoy P, Canik
S. The effects of insulin given prior to release of crossclamp
on coronary sinus lactate levels in coronary artery
surgery. [Article in Turkish] Anadolu Kardiyol Derg
2006;6:248-52.
19) Rao V, Christakis GT, Weisel RD, Ivanov J, Borger MA,
Cohen G. The insulin cardioplegia trial: myocardial protection
for urgent coronary artery bypass grafting. J Thorac
Cardiovasc Surg 2002;123:928-35.
20) Lazar HL. The insulin cardioplegia trial. J Thorac Cardiovasc
Surg 2002;123:842-4.